Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5

Gene Therapy

Volumn 18, Issue 7, 2011, Pages 646-655

  Nygrdas, M ^a   Aspelin, C ^a   Paavilainen, H ^a   Roytta M ^a   Waris, M ^a   Hukkanen, V ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Herpes simplex virus (HSV); interferon; interleukin; Toll like receptor

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; CONVALESCENCE; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; UPREGULATION; VIRUS REPLICATION;

ANIMALS; BRAIN; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; INTERFERON TYPE I; INTERLEUKIN-5; MICE; MICE, INBRED STRAINS; RNA, MESSENGER; TOLL-LIKE RECEPTORS;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 79960122565     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.4     Document Type: Article

References (73)

1. Amor S, Groome N, Linington C, Morris M, Dornmair K, Gardinier M et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994; 153: 4349-4356. (Pubitemid 24346829)
2. Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993; 23: 1364-1372. (Pubitemid 23165704)
3. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995; 25: 1951-1959.
4. Zamvil S, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579-621. (Pubitemid 20135640)
5. Tuohy V, Lu Z, Sobel R, Laursen R, Lees M. A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. J Immunol 1988; 141: 1126-1130.
6. Pettinelli C, McFarlin D. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol 1981; 127: 1420-1423. (Pubitemid 11021014)
7. Liblau R, Singer S, McDevitt H. Th1 and Th2 CD4+ T cells in the pathogenesis of organspecific autoimmune diseases. Immunol Today 1995; 16: 34-38.
8. Issazadeh S, Ljungdahl A, Höjeberg B, Mustafa M, Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 1995; 61: 205-212.
9. Ichikawa M, Koh C, Inoue A, Tsuyusaki J, Yamazaki M, Inaba Y et al. Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing- remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. J Neuroimmunol 2000; 102: 56-66.
10. Leonard J, Waldburger K, Goldman S. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-386.
11. Becher B, Durell B, Noelle R. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003; 112: 1186-1191. (Pubitemid 38056295)
12. Cua D, Sherlock J, Chen Y, Murphy C, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748. (Pubitemid 36227625)
13. Becher B, Durell B, Noelle R. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497. (Pubitemid 34919703)
14. Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, Sedgwick J et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240. (Pubitemid 40189432)
15. Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141. (Pubitemid 41541791)
16. Agrawal S, Yong V. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007; 79: 99-126.
17. Hofstetter H, Ibrahim S, Koczan D, Kruse N, Weishaupt A, Toyka K et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237: 123-130. (Pubitemid 43117208)
18. Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type .1. and 2 lineages. Nat Immunol 2005; 6: 1123-1132. (Pubitemid 41541790)
19. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562. (Pubitemid 38680433)
20. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13: 108-116. (Pubitemid 46341958)
21. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-352. (Pubitemid 41716771)
22. Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010; 162: 1-11.
23. Kennedy M, Torrance D, Picha K, Mohler K. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992; 149: 2496-2505.
24. Issazadeh S, Mustafa M, Ljungdahl A, Höjeberg B, Dagerlind A, Elde R et al. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995; 40: 579-590.
25. Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S et al. IL4 gene delivery to the CNS recruits regulatory T cells and induces clinical recovery in mouse models of multiple sclerosis. Gene Therapy 2008; 15: 504-515. (Pubitemid 351405090)
26. Furlan R, Poliani P, Galbiati F, Bergami A, Grimaldi L, Comi G et al. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 1998; 9: 2605-2617. (Pubitemid 29004633)
27. Furlan R, Poliani P, Marconi P, Bergami A, Ruffini F, Adorini L et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsingremitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Therapy 2001; 8: 13-19. (Pubitemid 32162411)
28. Broberg E, Salmi A, Hukkanen V. IL-4 is the key regulator in herpes simplex virus-based gene therapy of BALB/c experimental autoimmune encephalomyelitis. Neurosci Lett 2004; 364: 173-178. (Pubitemid 38757927)
29. Broberg E, Setä lä N, Röyttä M, Salmi A, Erälinna J, He B et al. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Therapy 2001; 8: 769-777. (Pubitemid 32509790)
30. Martino G, Furlan R, Galbiati F, Poliani P, Bergami A, Grimaldi L et al. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult Scler 1998; 4: 222-227. (Pubitemid 28410055)
31. Liblau R, Steinman L, Brocke S. Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int Immunol 1997; 9: 799-803. (Pubitemid 27226404)
32. Falcone M, Rajan A, Bloom B, Brosnan C. A critical role for IL-4 in regulating disease severity in experimental allergic encephalomyelitis as demonstrated in IL-4-deficient C57BL/6 mice and BALB/c mice. J Immunol 1998; 160: 4822-4830. (Pubitemid 28215316)
33. Bettelli E, Das M, Howard E, Weiner H, Sobel R, Kuchroo V. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 1998; 161: 3299-3306.
34. Sanderson C. Interleukin-5: an eosinophil growth and activation factor. Dev Biol Stand 1988; 69: 23-29.
35. Sanderson C. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-3109.
36. Wiesemann E, Klatt J, Sönmez D, Blasczyk R, Heidenreich F, Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive Tcells. J Neuroimmunol 2001; 119: 137-144. (Pubitemid 32781739)
37. Wiesemann E, Klatt J, Wenzel C, Heidenreich F, Windhagen A. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol 2003; 133: 454-460. (Pubitemid 37046972)
38. Sanna A, Fois M, Arru G, Huang Y, Link H, Pugliatti M et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006; 143: 357-362.
39. Weir C, Bernard C, Bäckström B. IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int Immunol 2003; 15: 1283-1289. (Pubitemid 37369321)
40. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1-16. (Pubitemid 47413193)
41. Lang K, Recher M, Junt T, Navarini A, Harris N, Freigang S et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11: 138-145. (Pubitemid 40321348)
42. Segal B, Chang J, Shevach E. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000; 164: 5683-5688. (Pubitemid 30389809)
43. Buenafe A, Bourdette D. Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis. J Neuroimmunol 2007; 182: 32-40. (Pubitemid 46026704)
44. Touil T, Fitzgerald D, Zhang G, Rostami A, Gran B. Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006; 177: 7505-7509. (Pubitemid 44846263)
45. Stevens J, Cook M. Latent herpes simplex virus in spinal ganglia of mice. Science 1971; 173: 843-845.
46. Stevens J, Cook M. Latent infections induced by herpes simplex viruses. Cancer Res 1973; 33: 1399-1401.
47. Chou J, Kern E, Whitley R, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266. (Pubitemid 120031840)
48. Markovitz N, Baunoch D, Roizman B. The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1. J Virol 1997; 71: 5560-5569. (Pubitemid 27258235)
49. Frampton AJ, Goins W, Nakano K, Burton E, Glorioso J. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Therapy 2005; 12: 891-901. (Pubitemid 40852207)
50. Hudson S, Dix R, Streilein J. Induction of encephalitis in SJL mice by intranasal infection with herpes simplex virus type 1: a possible model of herpes simplex encephalitis in humans. J Infect Dis 1991; 163: 720-727.
51. Broberg E, Peltoniemi J, Nyga°rdas M, Vahlberg T, Röyttä M, Hukkanen V. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J Virol 2004; 78: 13139-13152. (Pubitemid 39507821)
52. Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K et al. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 1999; 163: 40-49. (Pubitemid 29295822)
53. Prinz M, Schmidt H, Mildner A, Knobeloch K, Hanisch U, Raasch J et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675-686.
54. Guo B, Chang E, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008; 118: 1680-1690. (Pubitemid 351632372)
55. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003; 170: 4776-4784. (Pubitemid 36519987)
56. Axtell R, Steinman L. Type 1 interferons cool the inflamed brain. Immunity 2008; 28: 600-602. (Pubitemid 351636249)
57. Rudick R, Ransohoff R, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-627. (Pubitemid 26357887)
58. Rudick R, Ransohoff R, Lee J, Peppler R, Yu M, Mathisen P et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-1300. (Pubitemid 28240342)
59. Kozovska M, Hong J, Zang Y, Li S, Rivera V, Killian J et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53: 1692-1697. (Pubitemid 29530341)
60. Noronha A, Toscas A, Jensen M. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-153.
61. Mueller T, Terada T, Rosenberg I, Shibolet O, Podolsky D. Th2 cytokines down-regulate TLR expression and function in human intestinal epithelial cells. J Immunol 2006; 176: 5805-5814.
62. Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006; 116: 456-464. (Pubitemid 43228363)
63. Marta M, Andersson A, Isaksson M, Kämpe O, Lobell A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008; 38: 565-575.
64. Broberg E, Setälä N, Erä linna J, Salmi A, Röyttä M, Hukkanen V. Herpes simplex virus type 1 infection induces upregulation of interleukin-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice. J Interferon Cytokine Res 2002; 22: 641-651. (Pubitemid 35034522)
65. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
66. Smith P, Wolcott R, Chervenak R, Jennings S. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferongamma (IFN-gamma). Virology 1994; 202: 76-88. (Pubitemid 24241980)
67. Cantin E, Hinton D, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol 1995; 69: 4898-4905.
68. Peltoniemi J, Broberg E, Nygärdas M, Erä linna J, Waris M, Hukkanen V. Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy. Int Immunopharmacol 2006; 6: 817-829.
69. Furlan R, Bergami A, Brambilla E, Butti E, De Simoni M, Campagnoli M et al. HSV-1- mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Therapy 2007; 14: 93-98. (Pubitemid 44942870)
70. Lagunoff M, Roizman B. The regulation of synthesis and properties of the protein product of open reading frame P of the herpes simplex virus 1 genome. J Virol 1995; 69: 3615-3623.
71. Andreansky S, He B, van Cott J, McGhee J, Markert J, Gillespie G et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Therapy 1998; 5: 121-130. (Pubitemid 28045078)
72. Peltoniemi J, Broberg E, Halenius A, Setala N, Eralinna J, Salmi A et al. Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice. Clin Exp Immunol 2004; 137: 305-312. (Pubitemid 39013076)
73. Hukkanen V, Rehn T, Kajander R, Sjöroos M, Waris M. Time-resolved fluorometry PCR assay for rapid detection of herpes simplex virus in cerebrospinal fluid. J ClinMicrobiol 2000; 38: 3214-3218.